Skip to main content

Research Repository

Advanced Search

Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment

Contributors

U. Mony
Other

M. Jawad
Other

N. Russell
Other

M. Pallis
Other

Abstract

Relapse in acute myeloid leukaemia (AML) is mediated by survival of leukaemic stem cells following remission-induction chemotherapy. It would therefore be useful to identify therapeutic agents that target leukaemic stem cells. We devised a flow cytometric chemosensitivity assay allowing 48 h culture of leukaemic blasts in a defined microenvironment followed by enumeration of viable CD34+CD38−CD123+ leukaemic stem and progenitor cells (LSPC). The assay was used to investigate the LSPC response to cytosine arabinoside (Ara-C) and to the FLT3 inhibitor AG1296. There was a 3.6-fold increase in Ara-C-treated LSPC survival under defined ‘niche-like’ conditions compared to culture without microenvironmental support. Nine AML samples with internal tandem duplications of FLT3 (FLT3/ITDs) were treated with AG1296. Three samples were very sensitive (>50% kill) and 4 were moderately sensitive (10–50% kill) in bulk suspension culture without microenvironmental support. However, under defined ‘niche-like’ conditions, the survival of LSPC was enhanced rather than inhibited by AG1296 treatment. We conclude that an interaction between LSPC and a defined in vitro microenvironment models a chemoresistant niche. Our data point to a need to investigate more novel chemotherapeutic agents under these stringent conditions to identify agents that may be suitable to target minimal residual disease in AML.

Citation

(2008). Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment. Leukemia, 22, 1395-1401. https://doi.org/10.1038/leu.2008.125

Journal Article Type Article
Acceptance Date Apr 24, 2008
Online Publication Date May 29, 2008
Publication Date 2008-07
Deposit Date Apr 5, 2024
Journal Leukemia
Print ISSN 0887-6924
Electronic ISSN 1476-5551
Publisher Nature Publishing Group
Peer Reviewed Peer Reviewed
Volume 22
Pages 1395-1401
DOI https://doi.org/10.1038/leu.2008.125
Public URL https://nottingham-repository.worktribe.com/output/32755064
Publisher URL https://www.nature.com/articles/leu2008125